Global Optometry Equipment Market Set to Reach USD 1.68 Billion by 2028
June 12, 2024 10:30 ET
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Optometry Equipment Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The global optometry equipment market is...
Global Prescription Lens Market (2023-2034) to Grow by $33.8 Billion - Growth Opportunity Forecasts by Type, Coating, Application, and Region with Profiles of the Top 10+ Market Players
May 30, 2024 06:04 ET
|
Research and Markets
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "Global Prescription Lens Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
February 06, 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling
January 29, 2024 12:05 ET
|
Doheny Eye Institute
PASADENA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, is pleased to announce the publication of important new findings...
Global Diabetic Retinopathy Market Size, Share & Trends Analysis Report 2024-2030: Non-Proliferative Diabetic Retinopathy Accounted for the Largest Share, By Type in 2023
January 24, 2024 05:35 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative DR, Non-Proliferative DR), Management (Anti-VEGF...
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
January 23, 2024 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
December 21, 2023 05:50 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
December 04, 2023 14:45 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS
DESSY BONEVA, MD, FACS TO THE BOARD OF DIRECTORS Dr. Boneva is an experienced surgeon skilled in trauma, surgical
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
December 01, 2023 12:32 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. ANNOUNCES HIRING OF INTERIM CFO
Virender Ahluwalia will serve as Interim Chief Financial Officer
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
November 28, 2023 16:01 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS STEPHEN TANNENBAUM
TO THE COMPANY'S BUSINESS ADVISORY BOARD. RetinalGeniX is an ophthalmic R&D company